We screened 685 studies on Lung Cancer this month. These are the most important.
NSCLC: post-RT cardiac events linked to heart dose
- Clinically significant cardiac events that occur after high-dose thoracic radiation therapy in stage III NSCLC were associated with heart dose and cardiac risk and were observed relatively soon after treatment in a study of 127 patients.
- The findings highlight the necessity of minimizing heart doses to patients with stage III NSCLC.
Extensive SCLC: add-on bevacizumab boosts PFS, but not OS
- Combining bevacizumab with standard platinum plus etoposide chemotherapy does not improve OS in extensive disease SCLC, but does significantly improve PFS, according to a multicenter phase 3 trial.
- Treatment options for SCLC are limited, and these results highlight the need for further studies with novel and better antiangiogenic agents.